Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coya Therapeutics, Inc.COYA · Entity 6727 | Director · Chief Executive Officer | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coya Therapeutics, Inc.
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.73 · Expires 2036-01-22 | Direct | 293,983 |
Reported balance
After 2026-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 293,983 · Balance 293,983 F1: Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 26, 2026 08:00 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 293,983 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001193125-26-021724 · ownership.xml · derivative · entry 1 Swaminathan Arun · CIK 0002034346 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,983 Underlying: Common Stock, par value $0.0001 per share · 293,983 shares Expires 2036-01-22 F1 · derivative.exercise_date: Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 08:00 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 240,964 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000950170-25-004573 · ownership.xml · derivative · entry 1 Swaminathan Arun · CIK 0002034346 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,964 Underlying: Common Stock, par value $0.0001 per share · 240,964 shares Expires 2035-01-09 F1 · derivative.exercise_date: The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date. Read SEC document |
| November 13, 2024 Filed Nov 13, 2024 16:05 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 5,000 | $7.36 | $36,797.00 |
DisclosureSEC source: 0001493152-24-045120 · ownership.xml · nonDerivative · entry 1 Swaminathan Arun · CIK 0002034346 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 16:58 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 5,000 | $7.34 | $36,689.00 |
DisclosureSEC source: 0001493152-24-044819 · ownership.xml · nonDerivative · entry 1 Swaminathan Arun · CIK 0002034346 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.